358 related articles for article (PubMed ID: 10460149)
1. Engineered recombinant factor VII Q217 variants with altered inhibitor specificities.
Chang YJ; Hamaguchi N; Chang SC; Ruf W; Shen MC; Lin SW
Biochemistry; 1999 Aug; 38(34):10940-8. PubMed ID: 10460149
[TBL] [Abstract][Full Text] [Related]
2. Similar molecular interactions of factor VII and factor VIIa with the tissue factor region that allosterically regulates enzyme activity.
Kelley RF; Yang J; Eigenbrot C; Moran P; Peek M; Lipari MT; Kirchhofer D
Biochemistry; 2004 Feb; 43(5):1223-9. PubMed ID: 14756558
[TBL] [Abstract][Full Text] [Related]
3. Functional consequences of mutations in Ser-52 and Ser-60 in human blood coagulation factor VII.
Iino M; Foster DC; Kisiel W
Arch Biochem Biophys; 1998 Apr; 352(2):182-92. PubMed ID: 9587405
[TBL] [Abstract][Full Text] [Related]
4. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor.
Iakhiaev A; Ruf W; Rao LV
Thromb Haemost; 2001 Mar; 85(3):458-63. PubMed ID: 11307815
[TBL] [Abstract][Full Text] [Related]
5. Importance of factor VIIa Gla-domain residue Arg-36 for recognition of the macromolecular substrate factor X Gla-domain.
Ruf W; Shobe J; Rao SM; Dickinson CD; Olson A; Edgington TS
Biochemistry; 1999 Feb; 38(7):1957-66. PubMed ID: 10026279
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.
Petersen LC; Sprecher CA; Foster DC; Blumberg H; Hamamoto T; Kisiel W
Biochemistry; 1996 Jan; 35(1):266-72. PubMed ID: 8555184
[TBL] [Abstract][Full Text] [Related]
7. Hemophilia B with mutations at glycine-48 of factor IX exhibited delayed activation by the factor VIIa-tissue factor complex.
Wu PC; Hamaguchi N; Yu YS; Shen MC; Lin SW
Thromb Haemost; 2000 Oct; 84(4):626-34. PubMed ID: 11057861
[TBL] [Abstract][Full Text] [Related]
8. Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin.
Lormeau JC; Herault JP; Herbert JM
Thromb Haemost; 1996 Jul; 76(1):5-8. PubMed ID: 8819242
[TBL] [Abstract][Full Text] [Related]
9. Phospholipid regulates the activation of factor X by tissue factor/factor VIIa (TF/VIIa) via substrate and product interactions.
Hathcock JJ; Rusinova E; Gentry RD; Andree H; Nemerson Y
Biochemistry; 2005 Jun; 44(22):8187-97. PubMed ID: 15924438
[TBL] [Abstract][Full Text] [Related]
10. The lipoprotein-associated coagulation inhibitor.
Broze GJ; Girard TJ; Novotny WF
Prog Hemost Thromb; 1991; 10():243-68. PubMed ID: 2008533
[TBL] [Abstract][Full Text] [Related]
11. Large enhancement of functional activity of active site-inhibited factor VIIa due to protein dimerization: insights into mechanism of assembly/disassembly from tissue factor.
Stone MD; Harvey SB; Martinez MB; Bach RR; Nelsestuen GL
Biochemistry; 2005 Apr; 44(16):6321-30. PubMed ID: 15835921
[TBL] [Abstract][Full Text] [Related]
12. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol.
Sandset PM; Larsen ML; Abildgaard U; Lindahl AK; Odegaard OR
Blood Coagul Fibrinolysis; 1991 Jun; 2(3):425-33. PubMed ID: 1932528
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of activated coagulation factor VII by normal human plasma.
Dahl PE; Abildgaard U; Larsen ML; Tjensvoll L
Thromb Haemost; 1982 Dec; 48(3):253-6. PubMed ID: 7164015
[TBL] [Abstract][Full Text] [Related]
14. Mutagenesis studies toward understanding the mechanism of differential reactivity of factor Xa with the native and heparin-activated antithrombin.
Rezaie AR; Yang L; Manithody C
Biochemistry; 2004 Mar; 43(10):2898-905. PubMed ID: 15005625
[TBL] [Abstract][Full Text] [Related]
15. Expression, purification, and characterization of recombinant human factor X.
Rudolph AE; Mullane MP; Porche-Sorbet R; Miletich JP
Protein Expr Purif; 1997 Aug; 10(3):373-8. PubMed ID: 9268685
[TBL] [Abstract][Full Text] [Related]
16. Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor.
Jesty J; Lorenz A; Rodriguez J; Wun TC
Blood; 1996 Mar; 87(6):2301-7. PubMed ID: 8630391
[TBL] [Abstract][Full Text] [Related]
17. A cyclic pentapeptide derived from the second EGF-like domain of Factor VII is an inhibitor of tissue factor dependent coagulation and thrombus formation.
Orning L; Fischer PM; Hu CK; Agner E; Engebretsen M; Husbyn M; Petersen LB; Orvim U; Llinas M; Sakariassen KS
Thromb Haemost; 2002 Jan; 87(1):13-21. PubMed ID: 11848442
[TBL] [Abstract][Full Text] [Related]
18. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.
Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M
Thromb Haemost; 1998 Oct; 80(4):585-7. PubMed ID: 9798974
[TBL] [Abstract][Full Text] [Related]
19. Structure/function analyses of recombinant variants of human factor Xa: factor Xa incorporation into prothrombinase on the thrombin-activated platelet surface is not mimicked by synthetic phospholipid vesicles.
Larson PJ; Camire RM; Wong D; Fasano NC; Monroe DM; Tracy PB; High KA
Biochemistry; 1998 Apr; 37(14):5029-38. PubMed ID: 9538022
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a factor VII molecule carrying a mutation in the second epidermal growth factor-like domain.
Kavlie A; Orning L; Grindflek A; Stormorken H; Prydz H
Thromb Haemost; 1998 Jun; 79(6):1136-43. PubMed ID: 9657438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
